(Q37416404)

English

Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients

scientific article published on 17 March 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients (English)

1 reference

Europe PubMed Central

20 August 2017

0 references

0 references

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Sophia Li

1

1 reference

Europe PubMed Central

20 August 2017

Primal P Kaur

2

1 reference

Europe PubMed Central

20 August 2017

Virginia Chan

3

1 reference

Europe PubMed Central

20 August 2017

Steven Berney

4

1 reference

Europe PubMed Central

20 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 March 2009

1 reference

Europe PubMed Central

20 August 2017

Clinical Rheumatology

1 reference

Europe PubMed Central

20 August 2017

28

1 reference

Europe PubMed Central

20 August 2017

7

1 reference

Europe PubMed Central

20 August 2017

787-791

1 reference

Europe PubMed Central

20 August 2017

Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.

1 reference

https://api.crossref.org/works/10.1007%2FS10067-009-1149-4

21 January 2018

Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?

1 reference

https://api.crossref.org/works/10.1007%2FS10067-009-1149-4

21 January 2018

Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/19291350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19291350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/19291350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of tumour necrosis factor antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/19291350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19291350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/19291350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19291350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19291350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19291350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19291350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19291350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19291350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New drugs for rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19291350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor inhibitors for rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19291350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10067-009-1149-4

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37416404&oldid=2131500042"